Photo of Bakhos A. Tannous,  PhD

Bakhos A. Tannous, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-6026
Fax: (617) 724-1537

Bakhos A. Tannous, PhD

Massachusetts General Hospital


  • Professor, Neurology, Harvard Medical School
  • Associate Neuroscientist, Neurology, Massachusetts General Hospital
  • Director, Interdepartmental Neuroscience Center, Neurology, Massachusetts General Hospital
  • Co-Director, Molecular Neurogenetics Unit-East, Neurology, Massachusetts General Hospital
  • Director, MGH Viral Vector Development Facility, Neurology, Massachusetts General Hospital


Research Abstract

the Tannous laboratory focuses on developing experimental therapeutics against malignant pediatric and adult brain tumors including diffuse intrinsic pontine gliomas (DIPG) and glioblastomas (GBM).

One aspect of our work is to screen for drugs that can increase therapeutic efficacy for glioma stem-like cells (GSCs) by either: (1) eradicating these cells; (2) revert GSCs into a more differentiated state which can then respond to conventional therapies; and (3) sensitizing GSCs to current radio/chemotherapy. We do this using state-of-the-art multiplex secreted bioluminescent reporters which we have developed and optimized for high-throughput screening as well as in vivo imaging to monitor these processes non-invasively. One of our works was recently moved into a phase I trial to test hydroxyurea in combination with temozolomide for the treatment of adult GBM.

Another aspect of our work is to unravel the role of extracellular vesicles in GBM progression. Tumor cells have an insidious, “Trojan horse”-like mechanism to manipulate other tumor cells or normal cells in their environment using tumor-derived extracellular vesicles (tEVs). These vesicles, which are produced in abundance by tumor cells, contain both a representation and an enriched subset of cellular proteins and RNAs which can subvert the phenotype of recipient cells, including the normal cells in the tumor environs, as well as other tumor cells. While EVs can serve a normal function in cell-to-cell communication and the elimination of proteins and RNAs from cells, tEVs effectively “hijack” this process to promote oncogenicity. Our goal is to understand the role of tEV in gliomas intratumoral heterogeneity, phenotypic switch, therapeutic resistance, and immune suppression using different tEV-specific fluorescent and bioluminescent reporters which we have developed.

Our lab had a long interest in developing novel gene/cell therapeutic strategies against malignant gliomas using viral vectors, nanotherapeutics and cell-based therapies. We recently showered that a low dose of radiation can prime GBM for nanotherapeutic delivery leading to >10-fold uptake in the tumor. We are now exploring this observation to develop AAV, nanoparticles, and extracellular vesicles-based gene therapeutic approaches for immune checkpoint inhibition. Further, our lab was the first to show the potential of olfactory ensheathing glia, a fully differentiated cell, as a "trojan horse" for therapeutic delivery and exploring these cells for immune/cell therapy,

Working with our long-time collaborator Dr. Thomas Würdinger, we showed for the first time that blood platelets carry tumor-derived biomarkers and specific gene signatures that can distinguish patients with localized and metastasized tumors from healthy individuals. We called this phenomenon tumor-educated platelets or TEP. We are currently evaluating TEP for pan-cancer, multi-class detection as well as biomarker discovery and their potential for longitudinal disease monitoring and response to therapy. We are also evaluating the role of TEP in gliomagenesis, therapeutic resistance, and immune suppression.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Payne NC, Maksoud S, Tannous BA, Mazitschek R. A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader. Cell Chem Biol 2022. PubMed
  • Tian T, Liang R, Erel-Akbaba G, Saad L, Obeid PJ, Gao J, Chiocca EA, Weissleder R, Tannous BA. Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles. ACS Nano 2022; 16:1940-1953. PubMed
  • Li M, Schweiger MW, Ryan DJ, Nakano I, Carvalho LA, Tannous BA. Olfactory receptor 5B21 drives breast cancer metastasis. iScience 2021; 24:103519. PubMed
  • Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res 2021. PubMed
  • Cheah PS, Prabhakar S, Yellen D, Beauchamp RL, Zhang X, Kasamatsu S, Bronson RT, Thiele EA, Kwiatkowski DJ, Stemmer-Rachamimov A, György B, Ling KH, Kaneki M, Tannous BA, Ramesh V, Maguire CA, Breakefield XO. Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Sci Adv 2021. PubMed
  • Azam Z, To ST, Tannous BA. Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance. Adv Sci (Weinh) 2020; 7:2002015. PubMed
  • Sol N, In 't Veld SGJG, Vancura A, Tjerkstra M, Leurs C, Rustenburg F, Schellen P, Verschueren H, Post E, Zwaan K, Ramaker J, Wedekind LE, Tannous J, Ylstra B, Killestein J, Mateen F, Idema S, de Witt Hamer PC, Navis AC, Leenders WPJ, Hoeben A, Moraal B, Noske DP, Vandertop WP, Nilsson RJA, Tannous BA, Wesseling P, Reijneveld JC, Best MG, Wurdinger T. Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma. Cell Rep Med 2020; 1:100101. PubMed
  • Schweiger MW, Tannous BA. Small but Fierce: Tracking the Role of Extracellular Vesicles in Glioblastoma Progression and Therapeutic Resistance. Adv Biosyst 2020. PubMed
  • Badr CE, da Hora CC, Kirov AB, Tabet E, Amante R, Maksoud S, Nibbs AE, Fitzsimons E, Boukhali M, Chen JW, Chiu NHL, Nakano I, Haas W, Mazitschek R, Tannous BA. Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation. ACS Chem Biol 2020; 15:1445-1454. PubMed
  • Wang J, Tannous BA, Poznansky MC, Chen H. CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. Pharmacol. Res. 2020; 159:105010. PubMed
  • Narayan RS, Molenaar P, Teng J, Cornelissen FMG, Roelofs I, Menezes R, Dik R, Lagerweij T, Broersma Y, Petersen N, Marin Soto JA, Brands E, van Kuiken P, Lecca MC, Lenos KJ, In 't Veld SGJG, van Wieringen W, Lang FF, Sulman E, Verhaak R, Baumert BG, Stalpers LJA, Vermeulen L, Watts C, Bailey D, Slotman BJ, Versteeg R, Noske D, Sminia P, Tannous BA, Wurdinger T, Koster J, Westerman BA. A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. Nat Commun 2020; 11:2935. PubMed
  • Schweiger MW, Li M, Giovanazzi A, Fleming RL, Tabet EI, Nakano I, Würdinger T, Chiocca EA, Tian T, Tannous BA. Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NF-κB/STAT3 Signaling. Adv Biosyst 2020. PubMed
  • Yamashita D, Minata M, Ibrahim AN, Yamaguchi S, Coviello V, Bernstock JD, Harada S, Cerione RA, Tannous BA, La Motta C, Nakano I. Identification of ALDH1A3 as a viable therapeutic target in breast cancer metastasis-initiating cells. Mol Cancer Ther 2020. PubMed
  • Fan S, Tian T, Lv X, Lei X, Yang Z, Liu M, Liang F, Li S, Lin X, Lin Z, Xie S, Li B, Chen W, Pan G, Lin X, Ou Z, Zhang Y, Peng Y, Xiao L, Zhang L, Sun S, Zhang H, Lin S, Li Q, Zeng B, Kontos F, Ruan Y, Ferrone S, Lin D, Tannous BA, Li J. lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter. iScience 2020; 23:100835. PubMed
  • Eskandari SK, Sulkaj I, Melo MB, Li N, Allos H, Alhaddad JB, Kollar B, Borges TJ, Eskandari AS, Zinter MA, Cai S, Assaker JP, Choi JY, Al Dulaijan BS, Mansouri A, Haik Y, Tannous BA, van Son WJ, Leuvenink HGD, Pomahac B, Riella LV, Tang L, Seelen MAJ, Irvine DJ, Azzi JR. Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter. Sci Transl Med 2020. PubMed
  • Prabhakar S, Cheah PS, Zhang X, Zinter M, Gianatasio M, Hudry E, Bronson RT, Kwiatkowski DJ, Stemmer-Rachamimov A, Maguire CA, Sena-Esteves M, Tannous BA, Breakefield XO. Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Mol Ther Methods Clin Dev 2019; 15:18-26. PubMed
  • Zaborowski MP, Cheah PS, Zhang X, Bushko I, Lee K, Sammarco A, Zappulli V, Maas SLN, Allen RM, Rumde P, György B, Aufiero M, Schweiger MW, Lai CP, Weissleder R, Lee H, Vickers KC, Tannous BA, Breakefield XO. Membrane-bound Gaussia luciferase as a tool to track shedding of membrane proteins from the surface of extracellular vesicles. Sci Rep 2019; 9:17387. PubMed
  • Tannous BA, Badr CE. An allosteric inhibitor of SHP2 effectively targets PDGFRα-driven glioblastoma. 2019; 21:1348-1349. PubMed
  • da Hora CC, Schweiger MW, Wurdinger T, Tannous BA. Patient-Derived Glioma Models: From Patients to Dish to Animals. Cells 2019. PubMed
  • Carvalho LA, Tannous BA. Olfactory ensheathing cells travel their natural nasal pathway to deliver therapeutics to brain tumors. 2019; 10:4351-4353. PubMed
  • Zaborowski MP, Lee K, Na YJ, Sammarco A, Zhang X, Iwanicki M, Cheah PS, Lin HY, Zinter M, Chou CY, Fulci G, Tannous BA, Lai CP, Birrer MJ, Weissleder R, Lee H, Breakefield XO. Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Rep 2019; 27:255-268.e6. PubMed
  • Erel-Akbaba G, Carvalho LA, Tian T, Zinter M, Akbaba H, Obeid PJ, Chiocca EA, Weissleder R, Kantarci AG, Tannous BA. Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. ACS Nano 2019. PubMed
  • Tian T, Lv X, Pan G, Lu Y, Chen W, He W, Lei X, Zhang H, Liu M, Sun S, Ou Z, Lin X, Cai L, He L, Tu Z, Wang X, Tannous BA, Ferrone S, Li J, Fan S. Long noncoding RNA MPRL promotes mitochondrial fission and cisplatin chemosensitivity via disruption of pre-miRNA processing. Clin Cancer Res 2019. PubMed
  • Fan S, Tian T, Chen W, Lv X, Lei X, Zhang H, Sun S, Cai L, Pan G, He L, Ou Z, Lin X, Wang X, Perez MF, Tu Z, Ferrone S, Tannous BA, Li J. Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription. Cancer Res 2019; 79:1069-1084. PubMed
  • Minata M, Audia A, Shi J, Lu S, Bernstock J, Pavlyukov MS, Das A, Kim SH, Shin YJ, Lee Y, Koo H, Snigdha K, Waghmare I, Guo X, Mohyeldin A, Gallego-Perez D, Wang J, Chen D, Cheng P, Mukheef F, Contreras M, Reyes JF, Vaillant B, Sulman EP, Cheng SY, Markert JM, Tannous BA, Lu X, Kango-Singh M, Lee LJ, Nam DH, Nakano I, Bhat KP. Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation. Cell Rep 2019; 26:1893-1905.e7. PubMed
  • Chen W, Wang P, Lu Y, Jin T, Lei X, Liu M, Zhuang P, Liao J, Lin Z, Li B, Peng Y, Pan G, Lv X, Zhang H, Ou Z, Xie S, Lin X, Sun S, Ferrone S, Tannous BA, Ruan Y, Li J, Fan S. Decreased expression of mitochondrial miR-5787 contributes to chemoresistance by reprogramming glucose metabolism and inhibiting MT-CO3 translation. Theranostics 2019; 9:5739-5754. PubMed
  • Carvalho LA, Teng J, Fleming RL, Tabet EI, Zinter M, de Melo Reis RA, Tannous BA. Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy. Journal of the National Cancer Institute 2018. PubMed
  • Castellanos-Rizaldos E, Grimm DG, Tadigotla V, Hurley J, Healy J, Neal PL, Sher M, Venkatesan R, Karlovich C, Raponi M, Krug AK, Noerholm M, Tannous J, Tannous BA, Raez LE, Skog J. Exosome-based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients. Clin Cancer Res 2018. PubMed
  • Berenguer J, Lagerweij T, Zhao XW, Dusoswa S, van der Stoop P, Westerman B, de Gooijer MC, Zoetemelk M, Zomer A, Crommentuijn MHW, Wedekind LE, López-López À, Giovanazzi A, Bruch-Oms M, van der Meulen-Muileman IH, Reijmers RM, van Kuppevelt TH, García-Vallejo JJ, van Kooyk Y, Tannous BA, Wesseling P, Koppers-Lalic D, Vandertop WP, Noske DP, van Beusechem VW, van Rheenen J, Pegtel DM, van Tellingen O, Wurdinger T. Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. J Extracell Vesicles 2018; 7:1446660. PubMed
  • Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer M, Wakimoto H, Barazas M, Tannous M, Chi AS, Noske DP, Wesseling P, Wurdinger T, Batchelor TT, Tannous BA. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. 2017. PubMed
  • Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell 2017; 32:238-252.e9. PubMed
  • Lagerweij T, Dusoswa SA, Negrean A, Hendrikx EML, de Vries HE, Kole J, Garcia-Vallejo JJ, Mansvelder HD, Vandertop WP, Noske DP, Tannous BA, Musters RJP, van Kooyk Y, Wesseling P, Zhao XW, Wurdinger T. Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment. Angiogenesis 2017. PubMed
  • Lashgari G, Kantar RS, Tannous BA. Secreted Reporters for Monitoring Multiple Promoter Function. Methods Mol Biol 2017; 1651:33-47. PubMed
  • Landeira BS, Santana TT, Araújo JA, Tabet EI, Tannous BA, Schroeder T, Costa MR. Activity-Independent Effects of CREB on Neuronal Survival and Differentiation during Mouse Cerebral Cortex Development. Cereb Cortex 2016. PubMed
  • Li A, Wu Y, Linnoila J, Pulli B, Wang C, Zeller M, Ali M, Lewandrowski GK, Li J, Tricot B, Keliher E, Wojtkiewicz GR, Fulci G, Feng X, Tannous BA, Yao Z, Chen JW. Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models. Cancer Immunol Immunother 2016. PubMed
  • Lagerweij T, Hiddingh L, Biesmans D, Crommentuijn MH, Cloos J, Li XN, Kogiso M, Tannous BA, Vandertop WP, Noske DP, Kaspers GJ, Würdinger T, Hulleman E. A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer. 2016. PubMed
  • Best MG, Sol N, Tannous BA, Wesseling P, Wurdinger T. Re: a Word of Caution on New and Revolutionary Diagnostic Tests. Cancer Cell 2016; 29:143-4. PubMed
  • Kantar RS, Lashgari G, Tabet EI, Lewandrowski GK, Carvalho LA, Tannous BA. Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase. Sci Rep 2016; 6:26353. PubMed
  • Crommentuijn MH, Kantar R, Noske DP, Vandertop WP, Badr CE, Würdinger T, Maguire CA, Tannous BA. Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. Mol Ther Oncolytics 2016; 3:16017. PubMed
  • Crommentuijn MH, Maguire CA, Niers JM, Vandertop WP, Badr CE, Würdinger T, Tannous BA. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol 2015. PubMed
  • Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J, Ylstra B, Ameziane N, Dorsman J, Smit EF, Verheul HM, Noske DP, Reijneveld JC, Nilsson RJ, Tannous BA, Wesseling P, Wurdinger T. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell 2015; 28:666-76. PubMed
  • Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, Tannous J, Kuiper JL, Drees E, Grabowska M, van Keulen M, Heideman DA, Thunnissen E, Dingemans AC, Viteri S, Tannous BA, Drozdowskyj A, Rosell R, Smit EF, Wurdinger T. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. 2015. PubMed
  • Wong HK, Fatimy RE, Onodera C, Wei Z, Yi M, Mohan A, Gowrisankaran S, Karmali P, Marcusson E, Wakimoto H, Stephens R, Uhlmann EJ, Song JS, Tannous B, Krichevsky AM. The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. Mol Ther 2015. PubMed
  • Balaj L, Atai NA, Chen W, Mu D, Tannous BA, Breakefield XO, Skog J, Maguire CA. Heparin affinity purification of extracellular vesicles. Sci Rep 2015; 5:10266. PubMed
  • Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA, Breakefield XO. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun 2015; 6:7029. PubMed
  • Kuijten MM, Hannah Degeling M, Chen JW, Wojtkiewicz G, Waterman P, Weissleder R, Azzi J, Nicolay K, Tannous BA. Multimodal targeted high relaxivity thermosensitive liposome for in vivo imaging. Sci Rep 2015; 5:17220. PubMed
  • Teng J, Hejazi S, Badr CE, Tannous BA. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells 2014. PubMed
  • Hiddingh L, Tannous BA, Teng J, Tops B, Jeuken J, Hulleman E, Boots-Sprenger SH, Vandertop WP, Noske DP, Kaspers GJ, Wesseling P, Wurdinger T. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. 2014; 5:363-74. PubMed
  • Lai CP, Mardini O, Ericsson M, Prabhakar S, Maguire CA, Chen JW, Tannous BA, Breakefield XO. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 2014; 8:483-94. PubMed
  • van der Mijn JC, Sol N, Mellema W, Jimenez CR, Piersma SR, Dekker H, Schutte LM, Smit EF, Broxterman HJ, Skog J, Tannous BA, Wurdinger T, Verheul HM. Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. J Extracell Vesicles 2014; 3:25657. PubMed
  • Lai CP, Tannous BA, Breakefield XO. Noninvasive in vivo monitoring of extracellular vesicles. Methods Mol Biol 2014; 1098:249-58. PubMed
  • Lewandrowski GK, Magee CN, Mounayar M, Tannous BA, Azzi J. Simultaneous in vivo monitoring of regulatory and effector T lymphocytes using secreted Gaussia luciferase, Firefly luciferase, and secreted alkaline phosphatase. Methods Mol Biol 2014; 1098:211-27. PubMed
  • Elman JS, Murray RC, Murray RM, Wang F, Shen K, Gao S, Conway KE, Yarmush ML, Tannous BA, Weissleder R, Parekkadan B. Pharmacokinetics of natural and engineered secreted factors delivered by mesenchymal stromal cells. PLoS ONE 2014; 9:e89882. PubMed
  • Bovenberg MS, Degeling MH, Hejazi S, Amante RJ, van Keulen M, Jeuken JW, Akbaripanahi S, Vleggeert-Lankamp CL, Tannous M, Wesseling P, Wurdinger T, Tannous BA. Multiplex blood reporters for simultaneous monitoring of cellular processes. Anal Chem 2013; 85:10205-10. PubMed
  • Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, Zhou W, Kessler AF, Lewandrowski G, Hiddingh L, Sol N, Lagerweij T, Wedekind L, Niers JM, Barazas M, Nilsson RJ, Geerts D, De Witt Hamer PC, Hagemann C, Vandertop WP, Van Tellingen O, Noske DP, Gray NS, Würdinger T. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. Journal of the National Cancer Institute 2013; 105:1322-31. PubMed
  • Bovenberg MS, Degeling MH, Tannous BA. Cell-based immunotherapy against gliomas: from bench to bedside. Mol Ther 2013. PubMed
  • Bovenberg MS, Degeling MH, Tannous BA. Advances in stem cell therapy against gliomas. Trends Mol Med 2013. PubMed
  • Badr CE, Van Hoppe S, Dumbuya H, Tjon-Kon-Fat LA, Tannous BA. Targeting cancer cells with the natural compound obtusaquinone. Journal of the National Cancer Institute 2013. PubMed
  • Maguire CA, Bovenberg MS, Crommentuijn MH, Niers JM, Kerami M, Teng J, Sena-Esteves M, Badr CE, Tannous BA. Triple bioluminescence imaging for in vivo monitoring of cellular processes. Mol Ther Nucleic Acids 2013; 2:e99. PubMed
  • van Rijn S, Nilsson J, Noske DP, Vandertop WP, Tannous BA, Würdinger T. Functional multiplex reporter assay using tagged Gaussia luciferase. Sci Rep 2013; 3:1046. PubMed
  • Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, Tannous BA, Eichler AF, Fukumura D, Engelman JA, Jain RK. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A 2012; 109:E3119-27. PubMed
  • Niers JM, Chen JW, Lewandrowski G, Kerami M, Garanger E, Wojtkiewicz G, Waterman P, Keliher E, Weissleder R, Tannous BA. Single reporter for targeted multimodal in vivo imaging. J Am Chem Soc 2012; 134:5149-56. PubMed
  • Badr CE, Tannous BA. Bioluminescence imaging: progress and applications. Trends Biotechnol 2011. PubMed
  • Tannous BA, Teng J. Secreted blood reporters: insights and applications. Biotechnol Adv 2011; 29:997-1003. PubMed
  • Badr CE, Wurdinger T, Nilsson J, Niers JM, Whalen M, Degterev A, Tannous BA. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. 2011. PubMed
  • Niers JM, Kerami M, Pike L, Lewandrowski G, Tannous BA. Multimodal in vivo imaging and blood monitoring of intrinsic and extrinsic apoptosis. Mol Ther 2011. PubMed
  • Niers JM, Chen JW, Weissleder R, Tannous BA. Enhanced in vivo imaging of metabolically biotinylated cell surface reporters. Anal Chem 2011; 83:994-9. PubMed
  • Smits M, Mir SE, Nilsson RJ, van der Stoop PM, Niers JM, Marquez VE, Cloos J, Breakefield XO, Krichevsky AM, Noske DP, Tannous BA, Würdinger T. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 2011; 6:e16282. PubMed
  • Badr CE, Wurdinger T, Tannous BA. Functional Drug Screening Assay Reveals Potential Glioma Therapeutics. 2010. PubMed
  • Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky AM, Noske DP, Tannous BA, Würdinger T. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. 2010; 1:710-20. PubMed
  • Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, Peter Vandertop W, Cloos J, Tannous BA, Wesseling P, Aten JA, Noske DP, Van Noorden CJ, Würdinger T. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010; 18:244-57. PubMed
  • Prabhakar S, Brenner GJ, Sung B, Messerli SM, Mao J, Sena-Esteves M, Stemmer-Rachamimov A, Tannous B, Breakefield XO. Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Ther 2010; 17:266-74. PubMed
  • Sharma R, Tsuchiya M, Skobe Z, Tannous BA, Bartlett JD. The acid test of fluoride: how pH modulates toxicity. PLoS ONE 2010; 5:e10895. PubMed
  • Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 2009; 29:5923-40. PubMed
  • Maguire CA, Deliolanis NC, Pike L, Niers JM, Tjon-Kon-Fat LA, Sena-Esteves M, Tannous BA. Gaussia luciferase variant for high-throughput functional screening applications. Anal Chem 2009; 81:7102-6. PubMed
  • Tannous BA,Christensen AP,Pike L,Wurdinger T,Perry KF,Saydam O,Jacobs AH,Garcia-Anoveros J,Weissleder R,Sena-Esteves M,Corey DP,Breakefield XO. Mutant sodium channel for tumor therapy. Mol Ther 2009; 17:810-9. PubMed
  • Würdinger T, Tannous BA. Glioma angiogenesis: Towards novel RNA therapeutics. Cell Adh Migr 2009; 3:230-5. PubMed
  • Tannous B, Lee-Lewandrowski E, Sharples C, Brugge W, Bigatello L, Thompson T, Benzer T, Lewandrowski K. Comparison of conventional guaiac to four immunochemical methods for fecal occult blood testing: implications for clinical practice in hospital and outpatient settings. Clin Chim Acta 2009; 400:120-2. PubMed
  • Chung E, Yamashita H, Au P, Tannous BA, Fukumura D, Jain RK. Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 2009; 4:e8316. PubMed
  • Tannous BA. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 2009; 4:582-91. PubMed
  • van Vuurden DG, Yazdani M, Bosma I, Broekhuizen AJ, Postma TJ, Heimans JJ, van der Valk P, Aronica E, Tannous BA, Würdinger T, Kaspers GJ, Cloos J. Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. PLoS ONE 2009; 4:e5953. PubMed
  • Wurdinger T,Tannous BA,Saydam O,Skog J,Grau S,Soutschek J,Weissleder R,Breakefield XO,Krichevsky AM. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008; 14:382-93. PubMed
  • Deliolanis NC,Kasmieh R,Wurdinger T,Tannous BA,Shah K,Ntziachristos V. Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications. J Biomed Opt 2008; 13:044008. PubMed
  • Hewett JW, Nery FC, Niland B, Ge P, Tan P, Hadwiger P, Tannous BA, Sah DW, Breakefield XO. siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. Hum Mol Genet 2008; 17:1436-45. PubMed
  • Lewandrowski K, Flood J, Finn C, Tannous B, Farris AB, Benzer TI, Lee-Lewandrowski E. Implementation of point-of-care rapid urine testing for drugs of abuse in the emergency department of an academic medical center: impact on test utilization and ED length of stay. Am J Clin Pathol 2008; 129:796-801. PubMed
  • Wurdinger T,Badr C,Pike L,de Kleine R,Weissleder R,Breakefield XO,Tannous BA. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 2008; 5:171-3. PubMed
  • Hewett JW, Tannous B, Niland BP, Nery FC, Zeng J, Li Y, Breakefield XO. Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc Natl Acad Sci U S A 2007; 104:7271-6. PubMed
  • Badr CE, Hewett JW, Breakefield XO, Tannous BA. A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2007; 2:e571. PubMed
  • Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Metabolic biotinylation of cell surface receptors for in vivo imaging. Nat Methods 2006; 3:391-6. PubMed
  • Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 2005; 11:435-43. PubMed
  • Deliolanis NC, Dunham J, Wurdinger T, Figueiredo JL, Bakhos T, Ntziachristos V. In-vivo imaging of murine tumors using complete-angle projection fluorescence molecular tomography. J Biomed Opt ; 14:030509. PubMed
  • Teng J, Lashgari G, Tabet EI, Tannous BA. The natural compound obtusaquinone targets pediatric high-grade gliomas through ROS-mediated ER stress. ; 2:vdaa106. PubMed
  • Lee-Lewandrowski E, Januzzi JL, Green SM, Tannous B, Wu AH, Smith A, Wong A, Murakami MM, Kaczmarek J, Apple FS, Miller WL, Hartman K, Jaffe AS. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. Clin Chim Acta ; 386:20-4. PubMed
  • Badr CE, Niers JM, Tjon-Kon-Fat LA, Noske DP, Wurdinger T, Tannous BA. Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models. Mol Imaging ; 8:278-90. PubMed